Glaucoma drainage devices market seen reaching $1.42 billion by 2030

The glaucoma drainage devices market is projected to grow from $0.98 billion in 2026 to $1.42 billion by 2030, driven by rising glaucoma cases, more minimally invasive eye procedures and broader healthcare access. North America held the largest regional share in 2025, according to The Business Research Company.

Why it matters: - The glaucoma drainage devices market is expanding as more patients need surgery to control intraocular pressure and prevent vision loss. - The market’s growth reflects broader pressure on eye care systems as glaucoma cases rise and treatment options evolve. - The shift matters for device makers, ophthalmic surgery centers and health systems investing in advanced glaucoma care.

What happened: - The Business Research Company said the glaucoma drainage devices market is expected to increase from $0.89 billion in 2025 to $0.98 billion in 2026. - The report projects the market will reach $1.42 billion by 2030. - The forecast implies a 10.0% CAGR from 2025 to 2026 and a 9.7% CAGR through 2030. - North America held the largest share of the market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample report is available here. - The full report is available here.

The details: - Glaucoma drainage devices are surgical implants used to lower intraocular pressure in patients with glaucoma. - The devices create a controlled pathway for aqueous humor to exit the eye. - They are typically used when medication or laser therapy does not adequately control the condition. - Growth through 2026 is tied to rising glaucoma incidence, more ophthalmic surgical centers, greater use of surgical treatment, an aging population and broader access to specialized eye care. - Future demand is expected to be supported by preference for minimally invasive eye surgery, investment in new ophthalmic devices, expansion of glaucoma care programs, earlier diagnosis and better implant materials and design. - Expected trends include greater adoption of minimally invasive glaucoma implants, higher demand for valved drainage devices, stronger focus on long-term intraocular pressure management, broader use of biocompatible materials and more precise surgical implant designs.

Between the lines: - The market forecast points to a shift from standard glaucoma management toward more device-based intervention in harder-to-treat cases. - Rising healthcare spending and infrastructure expansion should widen access to procedures that rely on these implants. - The report’s emphasis on minimally invasive devices suggests competition will increasingly center on safety, precision and recovery time rather than only pressure control. - In the UK, glaucoma affects over 700,000 people, and nearly half are undiagnosed because the disease often has no symptoms, according to the NHS Confederation. - NHS waiting lists can extend up to 72 weeks, and major eye conditions are projected to increase 25% from 2022 to 2032. - UK healthcare spending rose 5.6% from 2022 to 2023 to about $317.63 billion (£292 billion), according to the Office for National Statistics.

What's next: - The market is likely to keep growing as ophthalmic providers adopt newer implants and more patients receive earlier treatment. - Further gains will likely depend on technological improvements in implant materials, broader surgical capacity and continued investment in glaucoma care. - Companies competing in the category will likely emphasize biocompatible materials, device precision and long-term pressure control.

The bottom line: - Glaucoma drainage devices are moving from a niche surgical option to a growing global market, with sales expected to climb steadily through 2030.